Clinical trials: Tirzepatide
Obesity, Overweight
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight.
- Trial name
- NCT06297616
- Testing
- LY3841136, Tirzepatide
- Where
- 3 sites in Japan
- Volunteers
- 128 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of LY3841136 in Overweight and Obese Participants
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
- Trial name
- NCT06345066
- Testing
- Tirzepatide, LY3841136
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Tirzepatide (LY3298176) in Healthy Participants
This study has four parts. Each participant will enroll in one part. Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC)…
- Trial name
- NCT03375463
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable…
- Trial name
- NCT06584916
- Testing
- Orforglipron
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company